Summary:
In pregnant women with type 1 diabetes, metformin adjunct therapy significantly reduced prandial insulin requirements and improved weight gain control compared to placebo with standard insulin treatment, though it was associated with no adverse effects on glycaemic control or neonatal outcomes.
| PICO | Description |
|---|---|
| Population | Pregnant women (n=126) with type 1 diabetes participating in a multicentre, randomised, double-blind, placebo-controlled study. |
| Intervention | Oral metformin administered alongside standard insulin therapy throughout pregnancy. |
| Comparison | Placebo administered alongside standard insulin therapy. |
| Outcome | While total insulin requirement change was not significantly different (33 IU vs. 27 IU; p = 0.193), prandial insulin increase was significantly lower in the metformin group (14 IU vs. 24 IU; p = 0.014). Weight gain was better controlled in metformin recipients, with greater benefit seen among those with higher BMI or insulin needs. No differences were observed in glycaemic control or neonatal outcomes between groups. |
Source: Juuma, Elina, et al. “The Effect of Metformin on Insulin Requirement, Glycaemic Control and Weight Gain in Type 1 Diabetes During Pregnancy—a Randomised, Placebo-Controlled Multicentre Study.” Read article here.
